These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
274 related items for PubMed ID: 16763797
21. [Effect of calcium dobesilate on progression of diabetic retinopathy]. Haas A, Trummer G, Eckhardt M, Schmut O, Uyguner I, Pfeiffer KP. Klin Monbl Augenheilkd; 1995 Jul; 207(1):17-21. PubMed ID: 7564132 [Abstract] [Full Text] [Related]
23. Blood-retina barrier permeability in diabetes during acute ACE-inhibition. Engler CB, Parving HH, Mathiesen ER, Larsen M, Lund-Andersen H. Acta Ophthalmol (Copenh); 1991 Oct; 69(5):581-5. PubMed ID: 1776410 [Abstract] [Full Text] [Related]
24. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial. Scott IU, Jackson GR, Quillen DA, Larsen M, Klein R, Liao J, Holfort S, Munch IC, Gardner TW. JAMA Ophthalmol; 2014 May; 132(5):535-43. PubMed ID: 24604308 [Abstract] [Full Text] [Related]
26. Calcium Dobesilate Prevents Neurodegeneration and Vascular Leakage in Experimental Diabetes. Solà-Adell C, Bogdanov P, Hernández C, Sampedro J, Valeri M, Garcia-Ramirez M, Pasquali C, Simó R. Curr Eye Res; 2017 Sep; 42(9):1273-1286. PubMed ID: 28574750 [Abstract] [Full Text] [Related]
27. Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function. Zhou Y, Qi C, Li S, Shao X, Mou S, Ni Z. Cell Physiol Biochem; 2018 Sep; 51(3):1119-1133. PubMed ID: 30476916 [Abstract] [Full Text] [Related]
32. [The plasma levels of endothelin in diabetic retinopathy and their changes after treatment with doxium]. Zhong H, Guo L. Hunan Yi Ke Da Xue Xue Bao; 1997 Sep; 22(1):56-8. PubMed ID: 9868029 [Abstract] [Full Text] [Related]
35. Treatment of early diabetic retinopathy with cyclandelate. Cunha-Vaz JG, Reis Fonseca J, Hagenouw JR. Br J Ophthalmol; 1977 Jun; 61(6):399-404. PubMed ID: 326306 [Abstract] [Full Text] [Related]
36. Vitreous fluorophotometry in patients with no or minimal diabetic retinopathy. Chahal P, Fallon TJ, Jennings SJ, Chowienczyk PJ, Kohner EM. Diabetes Care; 1986 Jun; 9(2):134-9. PubMed ID: 3698779 [Abstract] [Full Text] [Related]
37. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Retina; 2006 Jun; 26(9):999-1005. PubMed ID: 17151486 [Abstract] [Full Text] [Related]
38. An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy Trial. Gardner TW, Sander B, Larsen ML, Kunselman A, Tenhave T, Lund-Andersen H, Reimers J, Hubbard L, Blankenship GW, Quillen DA, Brod RD, Wilmarth MH, Post-Hansen H, Parving HH, Davis MD. Curr Eye Res; 2006 Jun; 31(6):535-47. PubMed ID: 16769613 [Abstract] [Full Text] [Related]
40. Blood-retinal barrier permeability and its relation to progression of retinopathy in patients with type 2 diabetes. A four-year follow-up study. Cunha-Vaz J, Leite E, Sousa JC, de Abreu JR. Graefes Arch Clin Exp Ophthalmol; 1993 Mar; 231(3):141-5. PubMed ID: 8462885 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]